



FOR IMMEDIATE RELEASE

**Nemucore Medical Innovations Announces Appointment of Dr. Michael V. Seiden to its Board of Directors and Clinical Advisory Board**

*Dr. Seiden brings unparalleled clinical and industry expertise in the field of oncology*

**WORCESTER, Mass. – December 9, 2015** – [Nemucore Medical Innovations, Inc.](#), a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced the election of Michael V. Seiden, M.D., Ph.D., Senior Vice President and Chief Medical Officer, McKesson Specialty Health (NYSE: MCK) and The US Oncology Network, to its Board of Directors, and his appointment to the Company’s Clinical Advisory Board. Dr. Seiden brings significant expertise and insights to Nemucore as a nationally recognized expert on ovarian cancer, for his accomplishments in the industry, and as the former CEO and President of Fox Chase Cancer Center, one of the top-ranked cancer programs in the country.

“Dr. Seiden’s expertise and leadership at all levels of clinical practice, patient care, research and corporate oversight will be of extraordinary benefit to Nemucore’s corporate governance and during our transition to a clinical development company,” said Timothy P. Coleman, Ph.D., Chairman, Chief Executive Officer and President of Nemucore. “Dr. Seiden shares our vision for building a patient-centric, sustainable biopharmaceutical organization focused on the most difficult-to-treat cancers, and joins at an important time in Nemucore’s development. We are poised to advance our lead ovarian cancer candidate NMI-900 into Phase 2b clinical trials in mid-2016, with two additional candidates anticipated to enter clinical trial development later next year.”

“The Nemucore team has made tremendous progress toward advancing multiple candidates into clinical development and I am delighted to be joining their Board of Directors and Clinical Advisory Board at this exciting time,” said Dr. Seiden. “Especially exciting to me is the opportunity to work with a company focused on women’s cancers, and to see Nemucore advance development of Müllerian Inhibitory Substance, now NMI-8000, on which I performed research while at Massachusetts General Hospital. I believe the MIS program could represent a true breakthrough in the treatment of ovarian cancer and I look forward to working with Nemucore leadership to help them achieve their vision.”

Dr. Seiden currently serves as Senior Vice President and Chief Medical Officer of McKesson Specialty Health and U.S. Oncology, where he is responsible for bringing the assets of McKesson to a 1000-member cancer physician community conducting clinical research, and various quality and performance initiatives and enhancing the delivery of high-quality, evidence-based care. In this role, he is also responsible for maximizing collaborative efforts between pharmaceutical and biotechnology partners and manufacturers to generate improved patient outcomes and value for all stakeholders in the dynamic environment of drug development and launch. Prior to joining McKesson, Dr. Seiden served as the Chief Executive Officer and President of Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center research facility and hospital. Under his leadership, Fox Chase merged with Temple University Health System in 2012. Previously, Dr. Seiden was a practicing oncologist at Massachusetts General Hospital, where he served as Chief of the Clinical Research Unit, Cancer Center Division, and as Associate Professor in Medicine at Harvard University. At

Massachusetts General Hospital, he launched its first-ever gynecologic cancer research initiative, which was later extended to partner affiliates Dana Farber Cancer Institute, Brigham and Women's Hospital, and Beth Israel Hospital to become one of the largest gynecological cancer research programs in the country. In 1995, Dr. Seiden was named Chair of the Clinical Research Committee for the Gynecologic Cancer Program within the Dana Farber / Harvard Cancer Center. He has been a practicing oncologist for more than 20 years.

Dr. Seiden received his bachelor's degree from Oberlin College and his medical and Ph.D. degrees from Washington University. He completed his residency at Massachusetts General Hospital, his fellowships in medical oncology and bone marrow transplant at Dana Farber Cancer Institute, and his post-doctoral fellowship at Brigham and Women's Hospital, Department of Pathology.

**About Nemucore Medical Innovations, Inc.**

Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women's cancers. Nemucore's most advanced candidate NMI-900, a potential therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in mid-2016. Two additional candidates are anticipated to enter clinical trial development later in 2016, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at [www.Nemucore.com](http://www.Nemucore.com).

# # #

**Contacts:**

Tim Coleman (investors)  
Nemucore Medical Innovations  
(508) 762-1017

BCC Partners (media)  
Karen Bergman  
(650) 323-1717  
kbergman@bccpartners.com  
Jen LaVin  
(207) 360-0473  
jlavin@bccpartners.com